Drugs / Imovax
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07399951 | Oct 2023 → Jun 2025 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT02956746 | Aug 2016 → Dec 2017 | rabies | Synermore Biologics Co., Ltd. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imovax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07399951 ↗ |
| Known as | RVi | “Imovax (RVi) and Rabavert (RVa) rabies vaccines” NCT02956746 ↗ |
| Modality | Vaccine | “Imovax (RVi) and Rabavert (RVa) rabies vaccines” NCT02956746 ↗ |